BioSystems
BioSystems, founded in 2023, is a life sciences technology company specializing in automation solutions for pharmaceutical manufacturing.
Profile
Automates microbial quality control testing for pharmaceutical manufacturing.
BioSystems, founded in 2023, is a life sciences technology company specializing in automation solutions for pharmaceutical manufacturing. Headquartered in Lowell, Massachusetts, the company focuses on streamlining microbial quality control (MQC) testing workflows, which are critical for ensuring the safety and efficacy of healthcare products like biologics, vaccines, and sterile injectables. BioSystems' flagship product, the Growth Direct system, automates traditionally manual MQC processes, reducing testing times and improving accuracy.
The company has a global presence, with operations in Switzerland, Germany, and the Netherlands. As of Q3 2025, BioSystems reported $7.8 million in revenue, marking a 3% increase from the previous year. The company also secured a record multi-system order from a Top 20 global biopharma customer, signaling growing adoption of its platform.
Despite these gains, BioSystems faces challenges in scaling its operations and achieving profitability, with a net loss of $11.5 million in Q3 2025. The company’s cash reserves stood at $42 million as of September 2025, providing runway into 2026. BioSystems continues to innovate, recently launching the RMBNucleus Mold Alarm software and preparing to introduce the Growth Direct Rapid Sterility application in 2024.
Products by BioSystems
- G Growth Direct The Growth Direct System by Rapid Micro Biosystems is an automated microbial detection platform designed for pharmaceutical and Be the first to review →
- R RMBNucleus Mold Alarm RMBNucleus Mold Alarm is an automated environmental mold detection system designed for pharmaceutical manufacturing quality control labs. It Be the first to review →
Who buys this
- Global pharmaceutical manufacturers
- Biologics and vaccine producers
- Cell and gene therapy manufacturers
- Sterile injectable manufacturers
- Clinical research organizations
Publicly disclosed clients
- Samsung Biologics
Strengths and what to watch
Strengths
- Flagship Growth Direct system automates manual MQC workflows, reducing testing times
- Strong adoption among Top 20 global biopharma companies
- Innovative product pipeline, including RMBNucleus Mold Alarm software
Watch for
- High net losses ($11.5 million in Q3 2025) despite revenue growth
- Dependence on a small number of large customers for revenue
- Challenges in scaling operations to meet increasing demand
Recent moves
Key Information
- Founded
- 2023
- Headquarters
- Lowell, Massachusetts
Frequently Asked Questions
What does BioSystems do?
BioSystems automates microbial quality control testing for pharmaceutical manufacturers. Their Growth Direct system streamlines manual MQC workflows, improving accuracy for biologics, vaccines, and sterile injectables. Founded in 2023, the Massachusetts-based company serves global biopharma clients with solutions reducing testing times while maintaining compliance.
How does the Growth Direct system work?
BioSystems' Growth Direct automates traditional manual microbial quality control processes. It accelerates testing timelines while maintaining accuracy for pharmaceutical products. The system is adopted by Top 20 biopharma companies for biologics and sterile manufacturing, though implementation requires operational scaling to meet demand.
Who uses BioSystems' technology?
Major pharmaceutical manufacturers rely on BioSystems, including Samsung Biologics. Their automation serves biologics producers, vaccine developers, and sterile injectable manufacturers. The company reports growing adoption among Top 20 global biopharma firms, though revenue depends heavily on a limited number of large-scale clients.
What are BioSystems' financial challenges?
Despite $7.8M Q3 2025 revenue (3% growth), BioSystems reported $11.5M net losses. While cash reserves ($42M) provide runway into 2026, scaling operations remains costly. The company balances innovation investments against profitability pressures as it expands its global footprint.
What new products is BioSystems developing?
BioSystems recently launched RMBNucleus Mold Alarm software and plans 2024's Growth Direct Rapid Sterility application. These innovations aim to strengthen their automated MQC pipeline for pharmaceutical clients, building on their flagship system's success in reducing manual testing workloads.
Where is BioSystems headquartered?
BioSystems operates from Lowell, Massachusetts, with additional facilities in Switzerland, Germany, and the Netherlands. This global presence supports pharmaceutical manufacturers worldwide, though North American operations form their core revenue base as of 2025 financial disclosures.
Sources
- www.sec.gov — Q3 2025 financial results and multi-system customer order
- www.sec.gov — 2023 revenue growth and product launches
- www.sec.gov — 2022 financial performance and Growth Direct system placements
- investors.rapidmicrobio.com — Q1 2025 financial results and strategic updates